Background Preterm neonates are usually not part of a traditional drug development
programme, however they are frequently administered medicines. Developing modelling …

Maturation of drug systemic clearance mechanisms during the postnatal period produces
dramatic and rapid changes in an infant's capacity to eliminate drugs. A tentative general …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus of midazolam 0.2 mg· kg− 1 was administered to 10 critically ill …

Background Midazolam is a first-line drug for the treatment of status epilepticus, both by
buccal and intravenous administration. In children and adolescents with obesity, midazolam …

This study aims to explore and characterize the role of pediatric sedation via rectal route. A
pediatric physiologically based pharmacokinetic-pharmacodynamic (PBPK/PD) model of …

The dose-dependent first-pass metabolism of midazolam, a cytochrome P450 (CYP) 3A
substrate, was separately estimated in the intestine and liver after administration into a …

Background The cytochrome P450 3A (CYP3A) isoforms are responsible for the metabolism
of a majority of therapeutic compounds, and they are abundant in the intestine and liver …

Objective: To evaluate the effects of intravenous midazolam on haemodynamic variables
and cerebral blood flow velocity (CBFV) and to determine the pharmacokinetics using a …

Abstract Objective: Cytochrome P450 III (CYP III) has previously been demonstrated in vitro
in fetal liver. Methods: A study was performed in 7 premature, 13 term neonates and 30 …

Background: Major changes in drug clearance and metabolism are observed during infancy,
in part based on ontogenic regulation of various metabolic pathways. Since paracetamol …